A 76-year-old man developed difficulties in walking due to back pain and visited a hospital. Multiple myeloma was suspected, and he was referred to our hospital. On admission, a peripheral blood test revealed neutrophilia (neutrophils, 17,788/L) and anemia (hemoglobin, 8.1 g/dL), and contrast-enhanced computed tomography demonstrated lytic bone lesions in the eighth thoracic vertebra, fourth lumbar vertebra, and left caput femoris. A bone marrow smear showed 37.6% neoplastic cells with increased segmented neutrophils and macrophages. The number of plasma cells was not increased. The neoplastic cells were large and pleomorphic; some had basophilic granules and foamy cytoplasm, showing hemophagocytosis (A, B). H&E staining showed diffuse proliferation of neoplastic cells (C). Immunohistochemically, they were positive for histiocytic markers [CD68 (D) and lysozyme (E)] and negative for lymphoid markers (CD3 and CD20), dendritic cell markers (CD21 and CD1a), a myeloid marker (myeloperoxidase), and a mast cell marker (c-kit). These data confirmed the diagnosis of histiocytic sarcoma. The patient received combination chemotherapy with therarubicin, cyclophosphamide, vincristine, and prednisolone.
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However, he rapidly developed pancytopenia and died of pneumonia. Histiocytic sarcoma is a very rare neoplasm, and bone marrow involvement is uncommon. Therefore, this patient's bone marrow smear images are particularly rare and valuable.
